ABBV
AbbVie Inc.
NYSE · Healthcare · Drug Manufacturers - General · US
$285.86
−0.05%Oct 18, 2026, 22:10 UTC
AbbVie Inc. announced that new and updated data from seven oncology assets will be presented at the 2026 ESMO Congress in Madrid from October 23 to 27.
Source:Oct 17, 2026, 21:45 UTC
AbbVie Inc., BRISTOL MYERS SQUIBB CO and Boehringer Ingelheim moved to intervene in the lawsuit over the 340B rebate pilot.
Source:Oct 8, 2026, 16:50 UTC
The U.S. Food and Drug Administration granted AbbVie Inc.'s Temab-A two Breakthrough Therapy designations for colorectal cancer and non-small cell lung cancer.
Source:Oct 7, 2026, 12:30 UTC
The U.S. Food and Drug Administration granted AbbVie Inc.’s Temab-A two Breakthrough Therapy designations.
Source:Oct 7, 2026, 12:30 UTC
The U.S. Food and Drug Administration granted telisotuzumab adizutecan two Breakthrough Therapy Designations, for colorectal cancer and non-small cell lung cancer.
Source:Oct 2, 2026, 20:53 UTC
AbbVie said on Friday it would participate in a US government pilot program aimed at testing a new rebate system for discounted medicines.
Source:Oct 2, 2026, 15:01 UTC
AbbVie received FDA approval for Juvmo, a new Parkinson's disease pill, with a commercial launch targeted for October 2026.
Source:Sep 30, 2026, 09:52 UTC
AbbVie announced that its investigational drug ABBV-295 showed up to 9.8% weight loss in a Phase 1 clinical trial, demonstrating "meaningful weight reduction."
Sep 29, 2026, 13:00 UTC
AbbVie partnered with ValkAI to apply advanced artificial intelligence.
Sep 28, 2026, 20:17 UTC
ADARx Pharmaceuticals, Inc. issued 5,255,542 shares of common stock to AbbVie Inc. in a private placement at $17.00 per share, raising approximately $89.3 million.
Sep 25, 2026, 22:04 UTC
The US Food and Drug Administration approved AbbVie's drug for Parkinson's disease in adults.
Sep 23, 2026, 17:45 UTC
AbbVie, Astex Pharmaceuticals, Bristol Myers Squibb, Johnson & Johnson, and Takeda jointly trained the federated AI model AISB-1-Fed on more than 20,000 proprietary protein–ligand structures in collaboration with Columbia University's AlQuraishi lab, achieving 52.1% high-quality interface predictions versus 35.6% for OpenFold3 Preview 2 and 40.9% for Boltz-2.
Source:Sep 22, 2026, 06:00 UTC
The European Commission approved AbbVie's RINVOQ (upadacitinib) for the treatment of active polyarticular juvenile idiopathic arthritis in patients aged two years and older in the European Union.
Source:Sep 21, 2026, 13:54 UTC
AbbVie agreed to purchase shares in a concurrent private placement that would result in AbbVie owning approximately 4.9% of ADARx Pharmaceuticals.
Source:Sep 21, 2026, 12:00 UTC
AbbVie and Iambic announced a multi-year collaboration to apply Iambic's AI platform to accelerate small molecule drug discovery in immunology, neuroscience and oncology.
Source:Sep 18, 2026, 12:30 UTC
AbbVie presented new real-world data supporting the effectiveness of VRAYLAR (cariprazine) in adults with major depressive disorder and bipolar I depression at Psych Congress 2026 in New Orleans.
Source:Sep 17, 2026, 13:45 UTC
Crohn's and Colitis Canada and AbbVie Canada announced the 2026 recipients of the AbbVie IBD Scholarship Program, awarding fifteen students across Canada $5,000 each.
Source:Sep 17, 2026, 12:00 UTC
Allergan Aesthetics, an AbbVie company, announced results from two single-center clinical studies evaluating targeted skincare regimens alone and in combination with DiamondGlow dermabrasion treatments in individuals taking medical weight loss medications, presented at the 2026 Science of Skin Summit.
Source:Sep 15, 2026, 12:00 UTC
Allergan Aesthetics announced it will advance scientific dialogue on skin longevity, aging biology and exosome science at the 2026 Science of Skin Summit, including a featured SkinMedica R&D panel introducing the FACTS Principles.
Source:Sep 11, 2026, 05:50 UTC
Allergan Aesthetics received approval from China's National Medical Products Administration for the infraorbital hollow indication of its hyaluronic acid product Juvederm Volbella (cross-linked sodium hyaluronate gel with lidocaine).
Source:Sep 10, 2026, 18:17 UTC
AbbVie Inc.'s board of directors declared a quarterly cash dividend of $1.73 per share.
Source:Sep 10, 2026, 12:55 UTC
AbbVie announced positive Phase III study results for atogepant in the treatment of menstrual migraine, reinforcing its leadership in the migraine field.
Sep 4, 2026, 15:53 UTC
AbbVie announced that its drug etentamig met key phase III goals in multiple myeloma, improving response rates and progression-free survival versus standard therapies.
Source:Sep 3, 2026, 13:24 UTC
AbbVie completed its $11 billion acquisition of Apogee Therapeutics.
Source:Sep 3, 2026, 13:15 UTC
AbbVie announced that its CERVINO Phase 3 trial met dual primary endpoints, with full results to be presented from September 23 to 26.
Sep 1, 2026, 12:05 UTC
Allergan Aesthetics, an AbbVie company, launched SkinMedica Barrier Calming Cream and HA5 Hydra Collagen Facial Mist as new regenerative skincare products in Irvine, California, on September 1, 2026.
Source:Aug 4, 2026, 13:09 UTC
AbbVie Inc. is seeking to raise at least $8 billion through an investment-grade bond offering to fund part of its acquisition of Apogee Therapeutics Inc.
Source:Jul 31, 2026, 11:47 UTC
AbbVie reported second-quarter 2026 financial results with diluted EPS of $2.03 on a GAAP basis and adjusted diluted EPS of $3.65, and net revenues of $16.990 billion, an increase of 10.2 percent on a reported basis.
Jul 9, 2026, 14:01 UTC
West Pharmaceutical Services completed the sale of its SmartDose 3.5mL platform to AbbVie.
Source: